Latest news

Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award

Debiopharm Launches Trilynx – A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head &…

Debiopharm Honored as a 2020 Swiss Biotech Success Story Winner for Outstanding Achievements over 40 Years

5e Challenge pour la Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop…

Debiopharm’s New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer

Debiopharm’s IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients

Nucleai Secured $6.5m Series-A Initial Closing Led by Debiopharm to Advance Ai-Powered Precision Oncology Platform